Table 3.
Univariate and multivariate analyses for PFS
| Characteristics | Univariate analysis PFS | Multivariate analysis PFS | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Sex | 0.65 | |||
| Female | 0.95 (0.75–1.19) | |||
| Male | 1 | |||
| Age | 0.80 | |||
| ≤ 70 years | 1 | |||
| > 70 years | 0.98 (0.81–1.17) | |||
| Etiology | 0.39 | |||
| Viral | 0.92 (0.77–1.11) | |||
| Non–viral | 1 | |||
| BCLC | 0.03 | 0.86 | ||
| B | 0.82 (0.68–0.98) | 0.98 (0.80–1.21) | ||
| C | 1 | 1 | ||
| AFP | < 0.01 | < 0.01 | ||
| < 400 ng/mL | 0.60 (0.49–0.74) | 0.74 (0.57–0.89) | ||
| ≥ 400 ng/mL | 1 | 1 | ||
| Child–Pugh | < 0.01 | |||
| A | 0.48 (0.31–0.75) | |||
| B | 1 | |||
| NLR | < 0.01 | < 0.01 | ||
| < 3 | 0.69 (0.57–0.84) | 0.81 (0.66–0.94) | ||
| ≥ 3 | 1 | 1 | ||
| EHD | 0.85 | |||
| Yes | 1 | |||
| No | 0.98 (0.81–1.19) | |||
| ALBI | < 0.01 | 0.01 | ||
| 1 | 0.53 (0.36–0.78) | 0.74 (0.45–0.95) | ||
| 2 | 1 | 1 | ||
| PS | < 0.01 | |||
| ≤ 1 | 0.28 (0.12–0.65) | |||
| > 1 | 1 | |||
| PVT | < 0.01 | |||
| Yes | 1 | |||
| No | 0.71 (0.56–0.89) | |||
| Decreased appetite | < 0.01 | |||
| Yes | 1 | |||
| No | 0.67 (0.53–0.84) | |||
| Decreased appetite | < 0.01 | 0.01 | ||
| G < 2 | 0.55 (0.38–0.80) | 0.73 (0.43–0.95) | ||
| G ≥ 2 | 1 | 1 | ||
| Fatigue | < 0.01 | < 0.01 | ||
| Yes | 1 | 1 | ||
| No | 0.74 (0.60–0.91) | 0.82 (0.65–0.95) | ||
| Fatigue | 0.11 | |||
| G < 2 | 0.75 (0.53–1.07) | |||
| G ≥ 2 | 1 | |||
| Proteinuria | 0.03 | 0.03 | ||
| Yes | 0.80 (0.66–0.98) | 0.79 (0.64–0.98) | ||
| No | 1 | 1 | ||
| Proteinuria | 0.07 | |||
| G < 2 | 1 | |||
| G ≥ 2 | 0.81 (0.64–1.02) | |||
| Hypertension | < 0.01 | |||
| Yes | 0.72 (0.59–0.87) | |||
| No | 1 | |||
| Hypertension | < 0.01 | < 0.01 | ||
| G < 2 | 1 | 1 | ||
| G ≥ 2 | 0.67 (0.54–0.83) | 0.68 (0.52–0.87) | ||
| Immunotoxicity | 0.14 | |||
| Yes | 1 | |||
| No | 0.81 (0.61–1.07) | |||
| Immunotoxicity | 0.01 | 0.07 | ||
| G < 2 | 0.55 (0.36–0.86) | 0.77 (0.42–1.06) | ||
| G ≥ 2 | 1 | 1 | ||
| Diarrhea | 0.01 | 0.01 | ||
| Yes | 0.67 (0.49–0.91) | 0.57 (0.38–0.85) | ||
| No | 1 | 1 | ||
| Diarrhea | 0.81 | |||
| G < 2 | 1 | |||
| G ≥ 2 | 0.93 (0.51–1.70) | |||
| Hypothyroidism | 0.07 | |||
| Yes | 0.71 (0.49–1.03) | |||
| No | 1 | |||
| Hypothyroidism | 0.17 | |||
| G < 2 | 1 | |||
| G ≥ 2 | 0.72 (0.45–1.15) | |||
| Other toxicity | 0.21 | |||
| Yes | 0.87 (0.70–1.08) | |||
| No | 1 | |||
| Other toxicity | 0.98 | |||
| < 2 | 1 | |||
| ≥ 2 | 1.00 (0.77–1.29) | |||
p < 0.05 are reported in bold
AFP alpha-feto-protein, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, EHD extrahepatic disease, G grade, NLR neutrophil-lymphocyte ratio, PFS progression-free survival, PS performance status, PVT portal vein thrombosis